Implementation of sequential therapy programmes - a pharmacist's view

被引:2
作者
Cairns, C [1 ]
机构
[1] St George Hosp, Pharm Acad Practice Unit, London SW17 0QT, England
关键词
D O I
10.1016/S0163-4453(98)92765-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Sequential antibiotic therapy has a number of advantages in terms of patient benefit and value for money in drug use. Introduction and maintenance of a process to ensure sequential therapy is multidisciplinary: involving clinicians, pharmacists, microbiologists and possibly nurses. The contribution of pharmacists is multi-faceted and involves senior and junior pharmacists working in a number of areas. Pharmacy managers will be involved at policy setting level through the Drug and Therapeutics committee and similar bodies. Purchasing and formulary pharmacists will be involved in negotiating purchasing agreements while clinical pharmacists provide data on the tests and outcomes of treatment. The drug information pharmacist is a valuable resource in searching and interpreting the available literature. Whatever system is used, clinical pharmacists have an important role in identifying patients and monitoring prescribing. In many schemes described in the literature, pharmacists have had an important role in auditing the effectiveness of sequential therapy. There may be scope for developing the clinical pharmacist's role further by devolving, under protocol, increased decision making and medicines management responsibilities.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 18 条
[1]  
ALLEN B, 1992, AUST J HOSP PHARM, V22, P343
[2]   Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: A pharmacoeconomic analysis [J].
AmodioGroton, M ;
Madu, A ;
Madu, CN ;
Briceland, LL ;
Seligman, M ;
McMaster, P ;
Miller, MH .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (06) :596-602
[3]   The economics of a pharmacy based central intravenous additive service for paediatric patients [J].
Armour, DJ ;
Cairns, CJ ;
Costello, I ;
Riley, SJ ;
Davies, EG .
PHARMACOECONOMICS, 1996, 10 (04) :386-394
[4]   ORAL VERSUS INTRAVENOUS ANTIBIOTICS FOR COMMUNITY-ACQUIRED LOWER RESPIRATORY-TRACT INFECTION IN A GENERAL-HOSPITAL - OPEN, RANDOMIZED CONTROLLED TRIAL [J].
CHAN, R ;
HEMERYCK, L ;
OREGAN, M ;
CLANCY, L ;
FEELY, J .
BRITISH MEDICAL JOURNAL, 1995, 310 (6991) :1360-1362
[5]  
COOKE J, 1993, ANN PHARMACOTHER, V27, P785
[6]   INTRAVENOUS-TO-ORAL STEPDOWN PROGRAM - 4 YEARS OF EXPERIENCE IN A LARGE TEACHING HOSPITAL [J].
FRIGHETTO, L ;
NICKOLOFF, D ;
MARTINUSEN, SM ;
MAMDANI, FS ;
JEWESSON, PJ .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (11) :1447-1451
[7]  
Hamilton-Miller J. M. T., 1996, Clin Microbiol Infect, V2, P12, DOI 10.1111/j.1469-0691.1996.tb00194.x
[8]   EDUCATIONAL ANTIBIOTIC ADVERTISING [J].
HARVEY, KJ ;
STEWART, R ;
HEMMING, M ;
NAISMITH, N ;
MOULDS, RFW .
MEDICAL JOURNAL OF AUSTRALIA, 1986, 145 (01) :28-32
[9]   PHARMACOECONOMIC BENEFIT OF ANTIBIOTIC STEP-DOWN THERAPY - CONVERTING PATIENTS FROM INTRAVENOUS CEFTRIAXONE TO ORAL CEFPODOXIME PROXETIL [J].
HENDRICKSON, JR ;
NORTH, DS .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (06) :561-565
[10]   ANTIMICROBIAL USAGE IN 43 HOSPITALS IN ENGLAND [J].
LEIGH, DA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1982, 9 (01) :75-84